Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insiders Are Buying Up Shares Of Sothebys (BID), Summit Hotel Properties Inc (INN), and TrovaGene Inc (TROV)

Page 1 of 2

One important field Insider Monkey follows is insider trades. Ultimately, who else would be most informed about developments in companies than the people most closely associated with these organizations? It comes as no surprise, therefore, that data shows insider purchases can be relatively effective in predicting how a stock performs over the long-term. This is why today’s spotlight shines on Sothebys (NYSE:BID), Summit Hotel Properties Inc (NYSE:INN) and TrovaGene Inc (NASDAQ:TROV), all of which had significant insider buying on August 12. Apart from looking at the specific insider purchases in these companies, we will also delve into how hedge funds are trading them, for a clearer picture of how good of an investment these stocks are.

insider trading insider buys

Chad McDermott /

But why is Insider Monkey keen on looking at hedge fund activity? General opinion is that hedge funds under perform the S&P500 based on net returns, but we are missing something very important here. Hedge funds generally pull in strong returns from their top small-cap stocks. Furthermore, they invest a lot of their resources into analyzing these stocks. They simply don’t take large enough positions in them relative to their portfolios to generate strong overall returns because their large-cap picks underperform the market. We share the top 15 small-cap stocks favored by the best hedge fund managers every quarter and this strategy has managed to outperform the S&P500 every year since it was launched in August 2012, returning over 123% and beating the market by more than 65 percentage points (read the details). Because of this, we know that collective hedge fund sentiment is extremely telling and valuable.

Let’s first take a look at global auction giant Sothebys (NYSE:BID). In four transactions yesterday, Chief Executive Officer, President and Director Thomas S. Smith Jr. acquired a total of 61,950 shares at an average price of $38.45 per share. This bullish move by the firm’s top executive, who assumed his post in March, comes after the company’s shares were battered by a weaker-than-expected second quarter. Shares of the firm closed down by 7.5% on August 7 after it reported a profit of $73.1 million, down from $87.8 million in last year’s comparable quarter. Adjusted earnings per share was $1.04, well below expectations of $1.26. The firm’s second quarter results were adversely affected by currency exchange headwinds and a significant art auction in London which was delayed until the third quarter. Year-to-date, the stock has fallen by almost 14%, while in the past 12 months, it is nearly flat, declining by just 0.03%. It should be noted, however, that there was a slight ebb of capital from Sothebys (NYSE:BID)’ stock in the first quarter, as total hedge fund holdings decreased by 4.77% quarter-over-quarter, despite only a 2.13% decline in the stock’s price. Nonetheless, 37.37% of the outstanding stock of the firm is owned by hedge funds we follow as of March 31, indicating that hedge funds think the stock is a good investment. The most bullish hedge fund on Sothebys among them was Dan Loeb’s Third Point, as it owned 6.65 million shares worth about $281.03 million at the end of the first quarter. Paul Orlin and Alex Porter’s Amici Capital bought the largest new stake in Sothebys in the first quarter, holding a $30.3 million position of 717,000 shares by March 31.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!